FLAM
First Light Asset Management Portfolio holdings
AUM
$771M
This Quarter Return
-4.96%
1 Year Return
+33.17%
3 Year Return
+208.13%
5 Year Return
+426.73%
10 Year Return
+3,318.8%
AUM
$876M
AUM Growth
+$876M
(-16%)
Cap. Flow
-$80M
Cap. Flow
% of AUM
-9.13%
Top 10 Holdings %
Top 10 Hldgs %
62.04%
Holding
42
New
6
Increased
11
Reduced
19
Closed
5
Top Buys
| 1 |
AnaptysBio
ANAB
|
$70M |
| 2 |
NeoGenomics
NEO
|
$27.3M |
| 3 |
Edgewise Therapeutics
EWTX
|
$23.6M |
| 4 |
Health Catalyst
HCAT
|
$23.5M |
| 5 |
Neuropace
NPCE
|
$19.5M |
Top Sells
| 1 |
FNA
Paragon 28, Inc.
FNA
|
$132M |
| 2 |
Insmed
INSM
|
$30.7M |
| 3 |
Pliant Therapeutics
PLRX
|
$22.1M |
| 4 |
AtriCure
ATRC
|
$21.1M |
| 5 |
Xenon Pharmaceuticals
XENE
|
$17.9M |
Sector Composition
| 1 | Healthcare | 99.39% |
| 2 | Technology | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
AnaptysBio
ANAB
$569M
| $86.1M | 9.84% | 4,633,602 +3,764,720 | +433% | +$70M |
|
2
Axogen
AXGN
$743M
| $82.8M | 9.45% | 4,474,215 -32,580 | -0.7% | -$603K |
|
|
CNTA
3
Centessa Pharmaceuticals
CNTA
$2.25B
| $70.1M | 8% | 4,874,124 -931,060 | -16% | -$13.4M |
|
|
4
NeoGenomics
NEO
$1.13B
| $57.3M | 6.55% | 6,042,822 +2,875,237 | +91% | +$27.3M |
|
5
Twist Bioscience
TWST
$1.63B
| $47.8M | 5.46% | 1,218,699 -7,556 | -0.6% | -$297K |
|
|
6
Health Catalyst
HCAT
$239M
| $47.3M | 5.4% | 10,436,807 +5,195,686 | +99% | +$23.5M |
|
|
7
AtriCure
ATRC
$1.84B
| $42.4M | 4.84% | 1,314,718 -654,503 | -33% | -$21.1M |
|
|
8
Edgewise Therapeutics
EWTX
$1.51B
| $40.8M | 4.65% | 1,852,290 +1,071,651 | +137% | +$23.6M |
|
|
PHLT
9
Performant Healthcare, Inc. Common Stock
PHLT
$603M
| $34.6M | 3.95% | 11,693,033 +346,384 | +3% | +$1.03M |
|
10
iRhythm Technologies
IRTC
$5.46B
| $34M | 3.89% | 325,046 -105,454 | -24% | -$11M |
|
11
Crinetics Pharmaceuticals
CRNX
$2.92B
| $28.7M | 3.28% | 855,419 -30,034 | -3% | -$1.01M |
|
12
Vera Therapeutics
VERA
$1.38B
| $28.2M | 3.23% | 1,175,879 -85,367 | -7% | -$2.05M |
|
13
MiMedx Group
MDXG
$1.05B
| $26.2M | 3% | 3,453,074 +109,213 | +3% | +$830K |
|
14
Ultragenyx Pharmaceutical
RARE
$2.89B
| $22.9M | 2.61% | 632,033 -131,574 | -17% | -$4.76M |
|
15
SI-BONE Inc
SIBN
$719M
| $22.6M | 2.58% | 1,612,408 +475,426 | +42% | +$6.67M |
|
|
16
Xenon Pharmaceuticals
XENE
$2.98B
| $21.1M | 2.41% | 627,904 -532,676 | -46% | -$17.9M |
|
|
17
Neuropace
NPCE
$303M
| $19.5M | 2.22% | +1,584,048 | New | +$19.5M |
|
18
Alignment Healthcare
ALHC
$3.24B
| $17.8M | 2.03% | +956,441 | New | +$17.8M |
|
19
Janux Therapeutics
JANX
$1.37B
| $17.8M | 2.03% | 658,824 +345,042 | +110% | +$9.32M |
|
20
Establishment Labs
ESTA
$1.2B
| $13.7M | 1.57% | +336,870 | New | +$13.7M |
|
21
Butterfly Network
BFLY
$405M
| $12.6M | 1.43% | 5,505,649 +1,511,029 | +38% | +$3.45M |
|
22
Guardant Health
GH
$8.41B
| $11.5M | 1.32% | 271,115 -38,274 | -12% | -$1.63M |
|
23
KORU Medical Systems
KRMD
$195M
| $11.3M | 1.29% | 4,454,926 -1,460,508 | -25% | -$3.71M |
|
24
Repligen
RGEN
$6.88B
| $11.2M | 1.28% | 87,850 +5,395 | +7% | +$686K |
|
25
Eledon Pharmaceuticals
ELDN
$155M
| $7.89M | 0.9% | 2,328,768 | – | – |
|